Revolutionizing Biologics Drug Discovery with AI: A Leap Forward with PEACCEL and Google Cloud

We’re thrilled to share an exciting milestone at PEACCEL – our disruptive AI discovery platform for biologics is setting new benchmarks in the pharmaceutical industry. By unlocking previously inaccessible spaces, we are identifying novel, life-changing drugs that were only possible in nature 1% of the time. Imagine the potential when we can screen 1 billion molecules in a single day!

🌐 A Game-Changing Collaboration: PEACCEL & Google Cloud 🌐

Our journey has taken an exhilarating turn as we were handpicked to join the Google Startup Program. This collaboration is not just an endorsement of our innovative approach; it’s a catalyst for exponential growth and impact. Here’s what this means for the pharmaceutical industry:

  1. Massive Scale Screening: From millions to over a billion molecules per day, pushing the boundaries of drug candidate identification from good to the BEST.
  2. Industrial Scale AI: Our platform’s scalability is now supercharged, ready for real-world applications at an industrial level.
  3. Unprecedented Computing Power: Access to a vast array of GPUs, expanding our computing capacity to accelerate drug development, reduce costs, and bring life-saving treatments to market faster.
  4. Robust Infrastructure & Tools: Leveraging Google’s state-of-the-art technology to enhance our research capabilities, foster innovation and drive forward the future of drug discovery.
Continue reading “Revolutionizing Biologics Drug Discovery with AI: A Leap Forward with PEACCEL and Google Cloud”

Unlocking the Future of Pharma: PEACCEL’s Breakthrough AI Platform for Biologics Wins French DeepTech Label.

We are thrilled to announce that PEACCEL has been awarded the prestigious French DeepTech label by BPI France, the public investment bank dedicated to innovation. This recognition is a testament to our commitment to pushing the boundaries of biotechnology with our groundbreaking AI discovery platform for Biologics.

Continue reading “Unlocking the Future of Pharma: PEACCEL’s Breakthrough AI Platform for Biologics Wins French DeepTech Label.”

Epistasis is a crucial issue: Non-Linear responses can hinder drug target identification or optimization of industrial production processes

Protein engineering in the context of metabolic engineering has a growing impact in industrial biotechnology and synthetic biology. Epistasis is a crucial issue: Non-Linear responses can hinder drug target identification or optimization of industrial production processes.

Discover our Editorial for a special issue of Frontiers in Molecular Biosciences: Machine learning, epistasis, and protein engineering: From sequence-structure-function relationships to regulation of metabolic pathways VOL I.

Read more: https://www.readcube.com/articles/10.3389/fmolb.2022.1098289

For more information:

PEACCEL
Making the world disease free
Contact: AI-team@peaccel.com
http://www.peaccel.com/

Maximize your next value creation opportunity for peptides, proteins, enzymes, antibodies & VHHs. Meet Peaccel’s delegates

Maximize your next value creation opportunity for peptides, proteins, enzymes, antibodies & VHHs.  Stand out of the reach of your competitors.

EPI_technology™ (Epistasis Processing Inside): Unique on the market, better & quicker for protein design & optimization  

Meet Peaccel’s delegates Jean-Marie Vallet and Jacob Weintraub at the Synthetic Biology-Based Therapies Summit, December 14-15 2022, Boston, US: https://synthetic-biology-therapeutics-summit.com

For more information:

PEACCEL
Making the world disease free
Contact: AI-team@peaccel.com
http://www.peaccel.com/

How the success rate of protein engineering projects is influenced by epistatic effects? A comparison of 15 state-of-the-art approaches

The recent development of structure prediction deep learning (DL) tools such as Alphafold2 (DeepMind), ESMfold (Meta) or ProteinMPNN (David Baker’s team) has revolutionized this area. Nevertheless, these DL tools are not suitable for predicting how individual amino acid changes alter protein function: they can’t predict epistaticeffects.

After protein folding powered by DeepMind and Meta the next challenge is to accurately predict epistasis ie. the impact of non-linear interactions of mutations within the protein sequence on the function.

Our recent review of Machine Learning (ML) and Deep Learning (DL) strategies examines how epistatic effects influence the success rate of protein engineering projects by comparing 15 state-of-the-art approaches (see Table 4: https://link.springer.com/protocol/10.1007/978-1-0716-2152-3_15/tables/4) and provides a general workflow for non-experts when using such learning strategies.

Read more: https://link.springer.com/protocol/10.1007/978-1-0716-2152-3_15#Abs1

For more information:

PEACCEL
Making the world disease free
Contact: AI-team@peaccel.com
http://www.peaccel.com/

After protein folding powered by Meta and DeepMind, the next challenge is to accurately predict epistasis

Epistasis dramatically influences the success of drug discovery projects: The real lead drug candidate is missed if epistasis is not taken into account.

After protein folding powered by Meta and DeepMind , the next challenge is to accurately predict epistasis ie. the impact of non-linear interactions of mutations within the protein sequence. PEACCEL’s founder, co-authored in ACS Catalysis a critical review on epistasis with its partners at Leibniz Institute of Plant Biochemistry.

Read more: https://pubs.acs.org/doi/10.1021/acscatal.2c01426#

For more information :

PEACCEL
Making the world disease free
Contact: AI-team@peaccel.com
http://www.peaccel.com/

PEACCEL (Paris, Fr) and JWIP & Patent Services, LLC (Boston, USA) sign a strategic partnership to increase the chances of success of your drugs

PEACCEL (Paris, Fr) and JWIP & Patent Services, LLC (Boston, USA) have signed a strategic partnership agreement.

As of October 2022, PEACCEL – The AI company for life sciences in Paris, and JWIP & Patent Services, LLC a Leading IP Firm in Boston, USA, combine their know-how and expertise to address the increasing needs of emerging AI-based drug discovery challenges for their large portfolio of customers and partners.
Combining the innov’SAR industrial AI platform developed by PEACCEL and the legal counsel provided by JWIP to accelerate critical collaborations and licensing between PEACCEL and key players in the pharmaceutical and chemical industries.

Continue reading “PEACCEL (Paris, Fr) and JWIP & Patent Services, LLC (Boston, USA) sign a strategic partnership to increase the chances of success of your drugs”

Accurate modeling of metabolic pathways for drug target identification and industrial production processes

PEACCEL and partners underline in the June 2022 issue of the peer-
reviewed journal Frontiers in Artificial intelligence how non-linearity is crucial when
modeling metabolic pathways for the identification of biomarkers of diseases or
optimizing industrial production processes.
Exemplified for:

  • The Entamoeba histolytica glycolysis, one of the major metabolic pathways of the parasite
  • The peroxide detoxification pathway of Trypanosoma cruzi
  • The industrial-scale penicillin fermentation process of Penicillium chrysogenum

Read more…

PEACCEL co-authored a critical review on VHH structural modelling approaches with its academic partners

VHH, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies. Unfortunately, most VHHs do not have 3D structures. This review presents the most extensive overview of structure prediction methods applied for the 3D modelling of a given VHH sequence (a total of 21). AlphaFold 2 and NanoNet appear to be the best tools to predict a structural model of VHH from its sequence.

Read more…

PEACCEL and SYNTHELIS have signed a strategic partnership to increase the chances of success of your drugs

PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.

Read more..

PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.

Read more..